Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.67 |
| ▸ | NPC1 | O15118 | 4/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | MGLL | Q99685 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL171227 | 0.84 | NPC1 (0.58) | RAB9ANPC1KMT2AMEN1MAPT | |
| SCHEMBL14147271 | 0.81 | RAB9A (0.58) | RAB9ANPC1KMT2AALDH1A1MEN1 | |
| SCHEMBL897183 | 0.81 | RAB9A (0.61) | RAB9ANPC1KMT2AALDH1A1MEN1 | |
| SCHEMBL21479385 | 0.80 | NPC1 (0.47) | RAB9ANPC1KMT2AALDH1A1MEN1 | |
| SCHEMBL2746369 | 0.79 | MGLL (0.47) | RAB9ANPC1KMT2AALDH1A1MEN1 | |
| SCHEMBL2440741 | 0.76 | ALDH1A1 (0.49) | RAB9ANPC1ALDH1A1GAAMGLL | |
| SCHEMBL29656505 | 0.75 | MGLL (0.46) | RAB9ANPC1KMT2AALDH1A1MEN1 | |
| SCHEMBL3573967 | 0.74 | MAPT (0.66) | RAB9ANPC1KMT2AALDH1A1MEN1 | |
| SCHEMBL14601827 | 0.74 | MAPT (0.57) | RAB9ANPC1KMT2AALDH1A1MEN1 | |
| SCHEMBL30475420 | 0.74 | GAA (0.58) | NPC1KMT2AALDH1A1MEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9758492-B2 | IDO inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-12 | — | — | US | disclosed |
| US-9758492-B2 | IDO inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-12 | — | — | US | disclosed |
| US-20160200674-A1 | IDO INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-07-14 | — | — | US | disclosed |
| US-20160200674-A1 | IDO INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-07-14 | — | — | US | disclosed |
| EP-2220078-B1 | BENZOMORPHOLINE DERIVATIVES AND METHODS OF USE | AMGEN INC (US) | 2013-05-22 | — | — | EP | disclosed |
| EP-2220078-B1 | BENZOMORPHOLINE DERIVATIVES AND METHODS OF USE | AMGEN INC (US) | 2013-05-22 | — | — | EP | disclosed |
| US-8338455-B2 | Pyridines or pyrimidines having 4-(hydrogenated 1-pyridyl- or hydrogenated 1-isoquinolyl rings, e.g., N-(4-chlorophenyl)-2-(pyridin-4-ylmethyl)-1,2,3,4-tetrahydroisoquinoline-5-carboxamide; kinase inhibitors; inflammation, angiogenesis and cancer | AMGEN INC. (US) | 2012-12-25 | — | — | US | disclosed |
| US-8338455-B2 | Pyridines or pyrimidines having 4-(hydrogenated 1-pyridyl- or hydrogenated 1-isoquinolyl rings, e.g., N-(4-chlorophenyl)-2-(pyridin-4-ylmethyl)-1,2,3,4-tetrahydroisoquinoline-5-carboxamide; kinase inhibitors; inflammation, angiogenesis and cancer | AMGEN INC. (US) | 2012-12-25 | — | — | US | disclosed |
| US-7795254-B2 | Benzomorpholine derivatives and methods of use | AMGEN INC. (US) | 2010-09-14 | — | — | US | disclosed |
| US-7795254-B2 | Benzomorpholine derivatives and methods of use | AMGEN INC. (US) | 2010-09-14 | — | — | US | disclosed |
| US-7795254-B2 | Benzomorpholine derivatives and methods of use | AMGEN INC. (US) | 2010-09-14 | — | — | US | disclosed |
| EP-2220078-A2 | BENZOMORPHOLINE DERIVATIVES AND METHODS OF USE | Amgen, Inc (US) | 2010-08-25 | — | — | EP | disclosed |
| US-20090149454-A1 | Benzomorpholine derivatives and methods of use | AMGEN INC. (US) | 2009-06-11 | — | — | US | disclosed |
| US-20090149454-A1 | Benzomorpholine derivatives and methods of use | AMGEN INC. (US) | 2009-06-11 | — | — | US | disclosed |
| US-20090149454-A1 | Benzomorpholine derivatives and methods of use | AMGEN INC. (US) | 2009-06-11 | — | — | US | disclosed |
| WO-2009058267-A2 | BENZOMORPHOLINE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2009-05-07 | — | — | WO | disclosed |
| WO-2009058267-A2 | BENZOMORPHOLINE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2009-05-07 | — | — | WO | disclosed |
| US-20080161346-A1 | Compounds and methods of use | AMGEN INC. (US) | 2008-07-03 | — | — | US | disclosed |
| US-20080161346-A1 | Compounds and methods of use | AMGEN INC. (US) | 2008-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149454-A1 | Benzomorpholine derivatives and methods of use | BDKRB2, BDKRB1, OPRK1 | RAB9A 2757/4885NPC1 1214/4885KMT2A 3986/4885 |
| US-20080161346-A1 | Compounds and methods of use | VHL, VEGFA, FLT1 | RAB9A 1727/4885NPC1 237/4885KMT2A 4330/4885 |
| US-20160200674-A1 | IDO INHIBITORS | IDO1, IDO2, INMT | RAB9A 3458/4885NPC1 3479/4885KMT2A 365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.